OMRT-3. Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment

To interrogate the factors driving therapy resistance in diffuse glioma, we collected and analyzed RNA and/or DNA sequencing data from temporally separated tumor pairs of 292 adult patients with IDH-wild-type or IDH-mutant glioma. Tumors recurred in distinct manners that were dependent on IDH mutation status and attributable to changes in histological feature composition, somatic alterations, and microenvironment interactions. Hypermutation and acquired CDKN2A deletions associated with an increase in proliferating stem-like malignant cells at recurrence in both glioma subtypes, reflecting active tumor growth. IDH-wild-type tumors were more invasive at recurrence, and their malignant cells exhibited increased expression of neuronal signaling programs that reflected a possible role for neuronal interactions in promoting glioma progression. Mesenchymal transition was associated with the presence of a specific myeloid cell state defined by unique ligand-receptor interactions with malignant cells. Collectively, our results uncover recurrence-associated changes that could be targetable to shape disease progression following initial diagnosis.

[1]  Dahua Xu,et al.  Pediatric Pan-Central Nervous System Tumor Methylome Analyses Reveal Immune-Related LncRNAs , 2022, Frontiers in Immunology.

[2]  S. Beck,et al.  Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion , 2021, Cell.

[3]  Jennie W. Taylor,et al.  Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. , 2021, Neuro-oncology.

[4]  Y. Saeys,et al.  Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization , 2021, Nature Neuroscience.

[5]  R. Verhaak,et al.  Perspective of mesenchymal transformation in glioblastoma , 2021, Acta neuropathologica communications.

[6]  Erwin G. Van Meir,et al.  N-cadherin upregulation mediates adaptive radioresistance in glioblastoma. , 2021, The Journal of clinical investigation.

[7]  B. Kamińska,et al.  Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages , 2021, Nature Communications.

[8]  Anna Luisa Di Stefano,et al.  Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities , 2021, Nature Cancer.

[9]  Gary D Bader,et al.  Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity , 2021, Nature Cancer.

[10]  M. Squatrito,et al.  Phenotypic mapping of pathological crosstalk between glioblastoma and innate immune cells by synthetic genetic tracing. , 2020, Cancer discovery.

[11]  S. Bicciato,et al.  Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in Glioblastoma , 2020, Nature Cancer.

[12]  Jennie W. Taylor,et al.  PATH-12. TEMOZOLOMIDE-INDUCED HYPERMUTATION IS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION, DISTANT RECURRENCE AND REDUCED SURVIVAL IN INITIALLY LOW GRADE IDH-MUTANT GLIOMAS , 2020 .

[13]  B. Zacharia,et al.  Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression , 2020, Nature Communications.

[14]  T. Jacques,et al.  Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity , 2020, Nature Communications.

[15]  H. Woo,et al.  Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma , 2020, Genome Biology.

[16]  H. Woo,et al.  Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma , 2020, Genome Biology.

[17]  Kevin C. Johnson,et al.  Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response , 2020, Nature Genetics.

[18]  R. Verhaak,et al.  iGLASS: Imaging integration into the Glioma Longitudinal AnalySiS Consortium. , 2020, Neuro-oncology.

[19]  Kevin Petrecca,et al.  Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy , 2020, Nature Communications.

[20]  S. Bakas,et al.  Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review , 2020, Journal of magnetic resonance imaging : JMRI.

[21]  Jennie W. Taylor,et al.  Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence, and reduced survival after transformation in initially low-grade IDH-mutant diffuse gliomas. , 2020 .

[22]  C. Brennan,et al.  Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells , 2020, Cell.

[23]  Raymond Y Huang,et al.  Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. , 2020, Neuro-oncology.

[24]  Raymond Y Huang,et al.  Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.

[25]  R. Steenbakkers,et al.  The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. , 2020, Radiology.

[26]  Christos Davatzikos,et al.  Integrated Biophysical Modeling and Image Analysis: Application to Neuro-Oncology. , 2020, Annual review of biomedical engineering.

[27]  Madeline G. Andrews,et al.  Outer Radial Glia-like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma. , 2020, Cell stem cell.

[28]  Arnold Kriegstein,et al.  The phenotypes of proliferating glioblastoma cells reside on a single axis of variation. , 2019, Cancer discovery.

[29]  Jeffrey H. Chuang,et al.  LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS , 2019, Nature.

[30]  T. Kuner,et al.  Glutamatergic synaptic input to glioma cells drives brain tumour progression , 2019, Nature.

[31]  Shawn M. Gillespie,et al.  Electrical and synaptic integration of glioma into neural circuits , 2019, Nature.

[32]  Kerstin B. Meyer,et al.  BBKNN: fast batch alignment of single cell transcriptomes , 2019, Bioinform..

[33]  Mariella G. Filbin,et al.  An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma , 2019, Cell.

[34]  P. Wesseling,et al.  Molecular pathology of tumors of the central nervous system , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[36]  Gabriele Schackert,et al.  Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. , 2019, Cancer cell.

[37]  Z. Szallasi,et al.  Neoantigen-directed immune escape in lung cancer evolution , 2019, Nature.

[38]  R. Rabadán,et al.  Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma , 2019, Nature Medicine.

[39]  R. Rabadán,et al.  Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma , 2019, Nature Medicine.

[40]  M. Ceccarelli,et al.  Single-cell transcriptome analysis of lineage diversity in high-grade glioma , 2018, Genome Medicine.

[41]  Christos Davatzikos,et al.  Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. , 2018, Cancer cell.

[42]  Wyeth W. Wasserman,et al.  Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer , 2018, Cell.

[43]  Fuhui Long,et al.  An anatomic transcriptional atlas of human glioblastoma , 2018, Science.

[44]  Sally Harrison,et al.  How to analyse the spatiotemporal tumour samples needed to investigate cancer evolution: A case study using paired primary and recurrent glioblastoma , 2018, International journal of cancer.

[45]  Xuan-jun Wang,et al.  Expression and purification of the human epidermal growth factor receptor extracellular domain. , 2018, Protein expression and purification.

[46]  Benjamin J. Raphael,et al.  Abstract PR03: Genetic mechanisms of immune evasion in colorectal cancer , 2018, Systems Immuno-Oncology.

[47]  Lucy F. Stead,et al.  Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium , 2018, Neuro-oncology.

[48]  Fabian J Theis,et al.  SCANPY: large-scale single-cell gene expression data analysis , 2018, Genome Biology.

[49]  A. Kriegstein,et al.  Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment , 2017, Genome Biology.

[50]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[51]  Steven D Chang,et al.  Single-Cell RNAseq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma , 2017, bioRxiv.

[52]  Lisa C. Wallace,et al.  Targeting Glioma Stem Cells through Combined BMI1 and EZH2 Inhibition , 2017, Nature Medicine.

[53]  Damien Y. Duveau,et al.  Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma , 2017, Nature.

[54]  Edward F. Chang,et al.  Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.

[55]  Christos Davatzikos,et al.  In Vivo Detection of EGFRvIII in Glioblastoma via Perfusion Magnetic Resonance Imaging Signature Consistent with Deep Peritumoral Infiltration: The ϕ-Index , 2017, Clinical Cancer Research.

[56]  M. Jackson,et al.  Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling , 2017, Oncogene.

[57]  Mariella G. Filbin,et al.  Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq , 2017, Science.

[58]  Mariella G. Filbin,et al.  Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma , 2016, Nature.

[59]  In-Hee Lee,et al.  Clonal evolution of glioblastoma under therapy , 2016, Nature Genetics.

[60]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[61]  E. Mardis,et al.  pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens , 2016, Genome Medicine.

[62]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[63]  G. Bergers,et al.  Glioblastoma: Defining Tumor Niches. , 2015, Trends in cancer.

[64]  In-Hee Lee,et al.  Spatiotemporal Evolution of the Primary Glioblastoma Genome. , 2015, Cancer cell.

[65]  Chibo Hong,et al.  DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. , 2015, Cancer cell.

[66]  Piero Carninci,et al.  A draft network of ligand–receptor-mediated multicellular signalling in human , 2015, Nature Communications.

[67]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[68]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[69]  Parag Mallick,et al.  Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion , 2015, Cell.

[70]  Gabriele Schackert,et al.  Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups , 2015, Acta Neuropathologica.

[71]  Jill S Barnholtz-Sloan,et al.  Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution , 2015, Genome research.

[72]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[73]  Sohrab P. Shah,et al.  TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data , 2014, Genome research.

[74]  Benjamin Schubert,et al.  OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..

[75]  Peter Canoll,et al.  MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma , 2014, Proceedings of the National Academy of Sciences.

[76]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[77]  Tom C. Freeman,et al.  Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation , 2014, Immunity.

[78]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[79]  Se Hoon Kim,et al.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. , 2013, Cancer cell.

[80]  P. Benos,et al.  Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3 , 2013, Proceedings of the National Academy of Sciences.

[81]  C. Pellet-Many,et al.  VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation , 2011, Molecular biology of the cell.

[82]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[83]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[84]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[85]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[86]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[87]  E. Shafrir,et al.  Molecular and Genetic , 2002 .

[88]  Ash A. Alizadeh,et al.  Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. , 2020, Methods in molecular biology.

[89]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.